Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Malaria is one of the world’s oldest known diseases, but it is a modern disease too - it continues to kill roughly 600,000 people each year, most of them children in Sub-Saharan Africa. Seasonal malaria chemoprevention provides antimalarial drugs to millions of African children during high-risk periods. At IDDO, Dhruv Darji works to improve this approach by analysing combined study data to identify optimal treatments. Real-world factors guide policy, enhance effectiveness and maximise impact in reducing malaria-related deaths.

Healthcare worker examining a child

World Malaria Day, marked on 25 April, highlights global efforts to eliminate malaria under the theme ‘Driven to end malaria’. A key intervention is seasonal malaria chemoprevention, in which antimalarial drugs are given to healthy young children during periods of high transmission. Each year, around 50 million children in Africa receive this treatment, targeting those most at risk and reducing the need for travel to distant health facilities.

Researchers are working to improve this approach. At the Infectious Diseases Data Observatory (IDDO) at the University of Oxford, Dhruv Darji is evaluating what combinations of antimalarial drugs, including combinations with malaria vaccines, work best for this kind of preventative malaria medication. Rather than relying solely on costly clinical trials, Dhruv used a method called network meta-analysis, which allows comparison of multiple treatments, even when they have not been directly tested against each other.

This approach reveals patterns that individual studies cannot detect, enabling researchers to rank treatment options and identify those most likely to be effective. It also supports more efficient use of existing data, particularly in resource-limited settings.

However, optimising malaria prevention requires consideration of real-world factors. These include drug resistance, variations in transmission intensity, age-related differences in effectiveness, and the impact of malnutrition. By combining individual-level data from multiple studies, researchers can explore how these factors influence outcomes.

The ultimate goal is to provide robust, evidence-based guidance to policymakers and health programmes. By identifying the most effective and context-specific strategies, this work aims to maximise the impact of seasonal malaria chemoprevention, improve resource allocation, and save more lives among vulnerable children.

The full story is available on the University website.